Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo.

Gerhard SiemeisterAnne MengelAmaury E Fernández-MontalvánWilhelm BoneJens SchröderSabine Zitzmann-KolbeHans BriemStefan PrechtlSimon J HoltonUrsula MönningOliver von AhsenSandra JohanssenArwed CleveVera PütterMarion HitchcockFranz von NussbaumMichael BrandsKarl ZiegelbauerDominik Mumberg

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Our findings suggest clinical proof-of-concept studies evaluating BAY 1816032 in combination with taxanes or PARP inhibitors to enhance their efficacy and potentially overcome resistance.

Keyphrases

dna damage
dna repair
dna damage response
water quality
induced apoptosis
oxidative stress
signaling pathway